最新ニュース Eli Lilly (NYSE:LLY) 株価情報

Eli Lilly

Eli Lilly is a drug firm with a focus on neuroscience, cardiometabolic, cancer, and immunology. Lilly's key products include Verzenio for cancer; Mounjaro, Zepbound, Jardiance, Trulicity, Humalog, and Humulin for cardiometabolic; and Taltz and Olumiant for immunology.

Eli Lilly and Co

News

Upgrades

Pre-Market Outlook

Analyst Ratings

Trading Ideas

HOOD

TTWO

主要なアナリストが株式レーティングを見直したトピックスを紹介する。アナリストのレーティング変更（格上げ・格下げを含む）はアナリストレーティングのページをご覧いただきたい。

ロビンフッドのアナリスト　市場への評価を変更

Equities

Markets

ASTS

DXCM

TSLA

先週木曜日、主要な米国株指数は反発を推移した。ダウ平均は0.2%高の3万9935ドル、一方でS＆P500は0.5%安の5392ドルで取引を終了した。ナスダックは0.9%安の17182ドルで終了した。

米国株式市場　テスラが市場を牽引　NBA契約でディズニーも上昇

Short Sellers

Short Ideas

Eli Lilly and Co (NYSE:LLY) のフロートに対する新しいショート比率は、前回の報告から14.06％上昇しています。同社は最近、ショートで売られた株は616万株あり、これは取引可能なすべての普通株の0.73％に相当します。平均してこの株のショートポジションをカバーするには、トレーダーは2.39日かかります。

イーライリリー社をショート比率から分析

HARVEST ELI LILLY HG CL U UNT ETF

Liberty Media Corporation - Series A Liberty Live Common Stock

Liberty Live Group

LIBERTY LIVE SERIES B by Liberty Media Corporation

Liberty Media Corporation - Series C Liberty Live Common Stock

Tidal Trust II Defiance Daily Target 2X Long LLY ETF

ELI LILLY ORD

Thursday, The FDA determined the shortage of Eli Lilly And Co&#8217;s (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>) tirzepatide injection, a glucagon-like peptide 1 (GLP-1) medication, has been resolved.
Tirzepatide injection, branded as Mounjaro and Zepbound, has been in shortage since 2022 due to increased demand.
The U.S. health regulator <a target="_blank" href="https://www.fda.gov/drugs/drug-safety-and-availability/fda-clarifies-policies-compounders-national-glp-1-supply-begins-stabilize" rel="noreferrer noopener">reminded</a> compounders of the legal restrictions on making copies of FDA-approved drugs.
The FDA noted that Novo Nordisk A/S&#8216; (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVO#NYSE">NVO</a>) semaglutide (Wegovy, Ozempic) is still in shortage.
Despite semaglutide being the active ingredient in Hims &amp; Hers Health Inc&#8217;s (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HIMS#NYSE">HIMS</a>) compounded GLP-1 product, a Truist analyst notes that the recent FDA commentary has reignited investor concerns about the long-term viability of compounded GLP-1 treatments once <a target="_blank" href="https://www.benzinga.com/news/24/10/41164688/hims-hers-health-stock-is-tumbling-thursday-heres-why" rel="noreferrer noopener">the supply shortage ends</a>.
Truist&#8217;s consumer survey reveals that approximately 10% of consumers currently use compounded GLP-1 medications, while 14% are on branded versions.
Also Read: <a target="_blank" href="https://www.benzinga.com/news/24/09/40944130/hims-hers-to-offer-access-to-compounded-diabetes-and-weight-loss-drugs-for-just-99month-to-certain-p" rel="noreferrer noopener">Hims &amp; Hers To Offer Access To Compounded Diabetes And Weight Loss Drugs For Just $99/Month To Certain Professional Personnel</a>.
Many people opting for compounded GLP-1s cite lower costs as the main reason, while others note that their primary care physicians are hesitant to prescribe the branded versions.
Hims &amp; Hers Health&#8217;s assertion that demand for its weight loss service could remain strong, even after supply shortages ease, as long as the company operates within compounding regulations and respects branded drug patents.
Based on third-quarter card data analysis, the analyst notes that Hims &amp; Hers Health&#8217;s Q3 2024 revenue is expected to exceed the company&#8217;s guidance range of $375 million to $380 million by approximately $5 million to $10 million.
The analyst also highlights that Hims &amp; Hers Health&#8217;s average transaction price was up 14% sequentially at $126.9 vs. ~$111 in the second quarter of 2024. Net orders for 3Q24 increased 3% sequentially from 2Q24.
Truist maintains a Hold rating for Hims &amp; Hers Health with a <a target="_blank" href="https://www.benzinga.com/quote/HIMS/analyst-ratings" rel="noreferrer noopener">price target of $23</a>.
Price Action: HIMS stock is up 0.18% at $17.16 at the last check Friday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/news/24/10/41189500/tesla-cio-quits-before-major-robotaxi-event-exec-departures-continue-in-2024" target="_blank" rel="noreferrer noopener">Tesla CIO Quits Before Major Robotaxi Event, Exec Departures Continue in 2024</a>.</li>
</ul>
Photo by Vidmir Rais via Pixabay

Analyst Color

Biotech

Health Care

Price Target

General

Hims & Hers Health, Inc. Class A Common Stock

HIMS

Hims & Hers Health Asserts Demand For Its Compounded Weight Loss Offering To Continue Despite Resolved Supply Shortages

In today's fast-paced and highly competitive business world, it is crucial for investors and industry followers to conduct comprehensive company evaluations. In this article, we will delve into an extensive industry comparison, evaluating Eli Lilly (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>) in relation to its major competitors in the Pharmaceuticals industry. By closely examining key financial metrics, market standing, and growth prospects, our objective is to provide valuable insights and highlight company's performance in the industry.
<h3>Eli Lilly Background</h3>
Eli Lilly is a drug firm with a focus on neuroscience, cardiometabolic, cancer, and immunology. Lilly's key products include Verzenio for cancer; Mounjaro, Zepbound, Jardiance, Trulicity, Humalog, and Humulin for cardiometabolic; and Taltz and Olumiant for immunology.
<table>
<thead>
<tr>
<th>Company</th>
<th>P/E</th>
<th>P/B</th>
<th>P/S</th>
<th>ROE</th>
<th>EBITDA (in billions)</th>
<th>Gross Profit (in billions)</th>
<th>Revenue Growth</th>
</tr>
</thead>
<tbody>
<tr>
<td>Eli Lilly and Co</td>
<td>109.06</td>
<td>58.79</td>
<td>20.56</td>
<td>22.5%</td>
<td>$4.12</td>
<td>$9.13</td>
<td>35.98%</td>
</tr>
<tr>
<td>Novo Nordisk AS</td>
<td>38.24</td>
<td>30.37</td>
<td>13.32</td>
<td>18.97%</td>
<td>$35.74</td>
<td>$57.79</td>
<td>25.34%</td>
</tr>
<tr>
<td>Johnson &amp; Johnson</td>
<td>24.28</td>
<td>5.40</td>
<td>4.56</td>
<td>6.62%</td>
<td>$7.8</td>
<td>$15.58</td>
<td>4.31%</td>
</tr>
<tr>
<td>Merck &amp; Co Inc</td>
<td>20.40</td>
<td>6.41</td>
<td>4.50</td>
<td>13.0%</td>
<td>$7.45</td>
<td>$12.37</td>
<td>7.16%</td>
</tr>
<tr>
<td>AstraZeneca PLC</td>
<td>37.83</td>
<td>6.12</td>
<td>4.95</td>
<td>5.01%</td>
<td>$4.12</td>
<td>$10.76</td>
<td>13.33%</td>
</tr>
<tr>
<td>Novartis AG</td>
<td>23.27</td>
<td>5.52</td>
<td>4.80</td>
<td>7.97%</td>
<td>$5.25</td>
<td>$9.7</td>
<td>9.6%</td>
</tr>
<tr>
<td>Sanofi SA</td>
<td>29.59</td>
<td>1.71</td>
<td>2.63</td>
<td>1.53%</td>
<td>$2.03</td>
<td>$7.97</td>
<td>6.53%</td>
</tr>
<tr>
<td>Zoetis Inc</td>
<td>37.45</td>
<td>17.42</td>
<td>9.83</td>
<td>12.45%</td>
<td>$0.97</td>
<td>$1.69</td>
<td>8.3%</td>
</tr>
<tr>
<td>GSK PLC</td>
<td>12.72</td>
<td>4.07</td>
<td>1.65</td>
<td>8.32%</td>
<td>$2.31</td>
<td>$5.76</td>
<td>9.84%</td>
</tr>
<tr>
<td>Takeda Pharmaceutical Co Ltd</td>
<td>43.08</td>
<td>0.82</td>
<td>1.46</td>
<td>1.26%</td>
<td>$388.51</td>
<td>$821.04</td>
<td>14.11%</td>
</tr>
<tr>
<td>Dr Reddy's Laboratories Ltd</td>
<td>19.96</td>
<td>3.76</td>
<td>3.85</td>
<td>4.84%</td>
<td>$21.72</td>
<td>$46.34</td>
<td>13.87%</td>
</tr>
<tr>
<td>Jazz Pharmaceuticals PLC</td>
<td>18.40</td>
<td>1.78</td>
<td>1.95</td>
<td>4.52%</td>
<td>$0.36</td>
<td>$0.91</td>
<td>6.95%</td>
</tr>
<tr>
<td>Corcept Therapeutics Inc</td>
<td>39.86</td>
<td>7.89</td>
<td>8.76</td>
<td>6.14%</td>
<td>$0.04</td>
<td>$0.16</td>
<td>39.15%</td>
</tr>
<tr>
<td>Organon &amp; Co</td>
<td>4.71</td>
<td>32.65</td>
<td>0.74</td>
<td>203.12%</td>
<td>$0.43</td>
<td>$0.94</td>
<td>-0.06%</td>
</tr>
<tr>
<td>Prestige Consumer Healthcare Inc</td>
<td>16.70</td>
<td>2.01</td>
<td>3.08</td>
<td>2.94%</td>
<td>$0.08</td>
<td>$0.15</td>
<td>-4.36%</td>
</tr>
<tr>
<td>Average</td>
<td>26.18</td>
<td>9.0</td>
<td>4.72</td>
<td>21.19%</td>
<td>$34.06</td>
<td>$70.8</td>
<td>11.0%</td>
</tr>
</tbody>
</table>
<style>
 table {
 width: 100%;
 border-collapse: collapse;
 font-family: Arial, sans-serif;
 font-size: 14px;
 }

 th, td {
 padding: 8px;
 text-align: left;
 }

 th {
 background-color: #293a5a;
 color: #fff;
 text-align: left;
 }

 tr:nth-child(even) {
 background-color: #f2f4f8;
 }

 tr:hover {
 background-color: #e1e4ea;
 }

 td:nth-child(3), td:nth-child(5) {
 text-align: left;
 }

 .dividend-amount {
 font-weight: bold;
 color: #0d6efd;
 }

 .dividend-frequency {
 font-size: 12px;
 color: #6c757d;
 }
 </style>By conducting an in-depth analysis of Eli Lilly, we can identify the following trends: 
<ul>
<li>
The Price to Earnings ratio of 109.06 for this company is 4.17x above the industry average, indicating a premium valuation associated with the stock.
</li>
<li>
It could be trading at a premium in relation to its book value, as indicated by its Price to Book ratio of 58.79 which exceeds the industry average by 6.53x.
</li>
<li>
The stock's relatively high Price to Sales ratio of 20.56, surpassing the industry average by 4.36x, may indicate an aspect of overvaluation in terms of sales performance.
</li>
<li>
With a Return on Equity (ROE) of 22.5% that is 1.31% above the industry average, it appears that the company exhibits efficient use of equity to generate profits.
</li>
<li>
The Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) of $4.12 Billion is 0.12x below the industry average, suggesting potential lower profitability or financial challenges.
</li>
<li>
The company has lower gross profit of $9.13 Billion, which indicates 0.13x below the industry average. This potentially indicates lower revenue after accounting for production costs.
</li>
<li>
The company's revenue growth of 35.98% is notably higher compared to the industry average of 11.0%, showcasing exceptional sales performance and strong demand for its products or services.
</li>
</ul>
<h3>Debt To Equity Ratio</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1728054011_0.png" alt="debt to equity" />
The debt-to-equity (D/E) ratio measures the financial leverage of a company by evaluating its debt relative to its equity.
Considering the debt-to-equity ratio in industry comparisons allows for a concise evaluation of a company's financial health and risk profile, aiding in informed decision-making.
By considering the Debt-to-Equity ratio, Eli Lilly can be compared to its top 4 peers, leading to the following observations:
<ul>
<li>
Eli Lilly is positioned in the middle in terms of the debt-to-equity ratio compared to its top 4 peers.
</li>
<li>
This suggests a balanced financial structure, where the company maintains a moderate level of debt while also relying on equity financing with a debt-to-equity ratio of 2.13.
</li>
</ul>
<h3>Key Takeaways</h3>
For Eli Lilly in the Pharmaceuticals industry, the PE, PB, and PS ratios are all high compared to peers, indicating potentially overvalued stock. On the other hand, the high ROE and revenue growth suggest strong profitability and future prospects. However, the low EBITDA and gross profit may raise concerns about operational efficiency and sustainability. Overall, Eli Lilly's performance in terms of valuation metrics is mixed compared to industry peers.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Evaluating Eli Lilly Against Peers In Pharmaceuticals Industry

NHS England has proposed a phased rollout of tirzepatide, a promising weight-loss drug, to benefit patients most likely to achieve significant clinical outcomes.
Tirzepatide, branded as Mounjaro and produced by Eli Lilly And Co (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>), has shown remarkable results in clinical trials. It offers greater weight loss than existing therapies like Novo Nordisk A/S&#8217; (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVO#NYSE">NVO</a>) and Ozempic (semaglutide).
In the SURMOUNT-4 trial, patients lost an average of 20.9% of their body weight in 36 weeks.
Also Read: <a target="_blank" href="https://www.benzinga.com/general/biotech/24/10/41168351/popular-weight-loss-drugs-like-ozempic-show-gap-between-clinical-trial-promises-and-real-world-us" rel="noreferrer noopener">Popular Weight Loss Drugs Like Ozempic Show Gap Between Clinical Trial Promises And Real-World Use, Study Reveals</a>.
The plan, currently under consultation, <a target="_blank" href="https://www.nice.org.uk/news/articles/consultation-on-nhs-england-proposals-for-a-phased-launch-of-obesity-injection" rel="noreferrer noopener">aims</a> to test various medication delivery models before expanding its availability.
Under draft guidance from an independent committee at the National Institute for Health and Care Excellence (NICE), tirzepatide has been recommended for patients living with obesity, with a maximum list price of 122 pounds ($159.6) per month for the highest dose.
The phased launch will integrate tirzepatide into community-based services and digital health platforms to expand accessibility.
The rollout will target up to 240,000 people in the first three years and evaluate cost-effective delivery models, including virtual clinics.
Eligible patients will be categorized based on their BMI and related health conditions. Initially, those with a BMI above 40 and three or more weight-related conditions, such as hypertension and cardiovascular disease, will qualify.
Obesity is a significant challenge for the NHS, with annual treatment costs reaching 11.4 billion pounds ($14.91 billion).
According to the Health Survey for England 2022, about 64% of adults in the country are overweight or obese.
The consultation period for the rollout plan is currently open, with final guidance from NICE expected later this year.
Earlier this week, Eli Lilly announced a&nbsp;$4.5 billion&nbsp;investment to create the Lilly Medicine Foundry, a new center for advanced manufacturing&nbsp;and drug development, as the company inches closer to becoming the first pharma company <a target="_blank" href="https://www.benzinga.com/general/biotech/24/10/41141028/eli-lilly-invests-4-5b-in-new-medicine-foundry-for-advanced-drug-manufacturing-to-push-us-pharma-" rel="noreferrer noopener">in the $1 trillion club</a>.
Price Action: LLY stock is down 0.23% at $883.56 at the last check Friday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/general/biotech/24/10/41184148/novo-nordiskastrazenecas-manufacturing-partner-thermo-fisher-questioned-over-manufacturing-lapses" target="_blank" rel="noreferrer noopener">Novo Nordisk/AstraZeneca&#8217;s Manufacturing Partner Thermo Fisher Questioned Over Manufacturing Lapses</a>.</li>
</ul>
Photo via Company

Government

Large Cap

England's NHS Proposes Phased Rollout of Eli Lilly's Mounjaro, Considers Digital Services to Boost Access

Texas Attorney General Ken Paxton has filed a lawsuit against several major insulin manufacturers and pharmacy benefit managers (PBMs), alleging a conspiracy to <a target="_blank" href="https://www.benzinga.com/markets/equities/24/08/40560002/governments-suing-pharmacy-benefit-managers-over-insulin-prices-have-long-benefited-from-their-r" rel="noreferrer noopener">inflate insulin prices</a>.
The <a target="_blank" href="https://www.texasattorneygeneral.gov/news/releases/attorney-general-ken-paxton-sues-big-pharma-drug-manufacturers-and-pharmacy-benefit-managers" rel="noreferrer noopener">lawsuit</a> targets pharmaceutical companies such as Eli Lilly And Co (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>) and PBMs, including Cigna Corp's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CI#NYSE">CI</a>) Express Scripts and CVS Health Inc's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CVS#NYSE">CVS</a>) CVS Pharmacy, accusing them of engaging in an unlawful scheme to raise insulin prices.
Also Read: <a target="_blank" href="https://www.benzinga.com/news/large-cap/24/09/40964870/us-federal-trade-commission-sues-cvs-health-cigna-unitedhealths-pharmacy-benefit-managers-for-infl" rel="noreferrer noopener">US Federal Trade Commission Sues CVS Health, Cigna, UnitedHealth's Pharmacy Benefit Managers For Inflating Insulin Prices</a>.
According to the lawsuit, insulin manufacturers artificially raised the prices of their drugs while paying PBMs a significant, undisclosed portion in return for preferred placement in PBM offerings.
The PBMs allegedly rewarded the manufacturers with the highest list prices by giving their products preferred status while excluding more affordable alternatives.
These insulin drugs, which cost manufacturers less than $2 to produce, were introduced in the late 1990s at $20 per vial. However, prices have now soared to between $300 and $700 per vial.
Over the past decade, some manufacturers have raised insulin prices by as much as 1,000%.
Paxton expressed outrage over the alleged scheme, stating, "This is a disturbing conspiracy by which pharmaceutical companies were intentionally and artificially inflating the price of insulin. Big Pharma insulin manufacturers and PBMs worked together to take advantage of diabetes patients and drive prices as high as they could." He vowed to hold these companies accountable for their actions.
The complaint further claims that while PBMs have publicly positioned themselves as entities working to reduce drug prices and improve treatment access, their actions tell a different story.
The lawsuit argues that the PBMs have colluded with insulin manufacturers to manipulate the market for their financial gain, all at the expense of Texas diabetics and healthcare payors.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/markets/equities/24/10/41171469/uber-avride-join-forces-for-autonomous-delivery-partners-with-enso-for-low-emission-ev-tires" target="_blank" rel="noreferrer noopener">Uber &amp; Avride Join Forces for Autonomous Delivery; Partners With ENSO For Low-Emission EV Tires</a></li>
</ul>
Photo by towfiqu barbhuiya via unsplash

Legal

Texas Attorney General Sues Insulin Manufacturers and Pharmacy Benefit Managers Over Price-Fixing Conspiracy That Increased Prices by 1,000%

In the preceding three months, 20 analysts have released ratings for Eli Lilly (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>), presenting a wide array of perspectives from bullish to bearish.
The table below offers a condensed view of their recent ratings, showcasing the changing sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;">Bullish</th>
<th style="text-align: right;">Somewhat Bullish</th>
<th style="text-align: right;">Indifferent</th>
<th style="text-align: right;">Somewhat Bearish</th>
<th style="text-align: right;">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td style="text-align: right;">8</td>
<td style="text-align: right;">12</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td style="text-align: right;">5</td>
<td style="text-align: right;">5</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">4</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
Insights from analysts' 12-month price targets are revealed, presenting an average target of $992.05, a high estimate of $1125.00, and a low estimate of $884.00. Witnessing a positive shift, the current average has risen by 7.74% from the previous average price target of $920.74.
<img src="https://www.benzinga.com/files/images/story/2024/1727978449_0.png" alt="price target chart" />
<h2>Investigating Analyst Ratings: An Elaborate Study</h2>
In examining recent analyst actions, we gain insights into how financial experts perceive Eli Lilly. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>James Shin</td>
<td>Deutsche Bank</td>
<td>Maintains</td>
<td>Buy</td>
<td>$1025.00</td>
<td>$1025.00</td>
</tr>
<tr>
<td>Louise Chen</td>
<td>Cantor Fitzgerald</td>
<td>Maintains</td>
<td>Overweight</td>
<td>$885.00</td>
<td>$885.00</td>
</tr>
<tr>
<td>Chris Schott</td>
<td>JP Morgan</td>
<td>Raises</td>
<td>Overweight</td>
<td>$1100.00</td>
<td>$1050.00</td>
</tr>
<tr>
<td>Peter Verdult</td>
<td>Citigroup</td>
<td>Announces</td>
<td>Buy</td>
<td>$1060.00</td>
<td>-</td>
</tr>
<tr>
<td>Louise Chen</td>
<td>Cantor Fitzgerald</td>
<td>Maintains</td>
<td>Overweight</td>
<td>$885.00</td>
<td>$885.00</td>
</tr>
<tr>
<td>Terence Flynn</td>
<td>Morgan Stanley</td>
<td>Maintains</td>
<td>Overweight</td>
<td>$1106.00</td>
<td>$1106.00</td>
</tr>
<tr>
<td>Louise Chen</td>
<td>Cantor Fitzgerald</td>
<td>Maintains</td>
<td>Overweight</td>
<td>$885.00</td>
<td>$885.00</td>
</tr>
<tr>
<td>Seamus Fernandez</td>
<td>Guggenheim</td>
<td>Raises</td>
<td>Buy</td>
<td>$1030.00</td>
<td>$884.00</td>
</tr>
<tr>
<td>Kerry Holford</td>
<td>Berenberg</td>
<td>Raises</td>
<td>Buy</td>
<td>$1050.00</td>
<td>$1000.00</td>
</tr>
<tr>
<td>James Shin</td>
<td>Deutsche Bank</td>
<td>Raises</td>
<td>Buy</td>
<td>$1025.00</td>
<td>$725.00</td>
</tr>
<tr>
<td>Mohit Bansal</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Overweight</td>
<td>$1000.00</td>
<td>$875.00</td>
</tr>
<tr>
<td>Evan Seigerman</td>
<td>BMO Capital</td>
<td>Raises</td>
<td>Outperform</td>
<td>$1101.00</td>
<td>$1001.00</td>
</tr>
<tr>
<td>Geoff Meacham</td>
<td>B of A Securities</td>
<td>Raises</td>
<td>Buy</td>
<td>$1125.00</td>
<td>$1000.00</td>
</tr>
<tr>
<td>Seamus Fernandez</td>
<td>Guggenheim</td>
<td>Raises</td>
<td>Buy</td>
<td>$884.00</td>
<td>$855.00</td>
</tr>
<tr>
<td>Louise Chen</td>
<td>Cantor Fitzgerald</td>
<td>Maintains</td>
<td>Overweight</td>
<td>$885.00</td>
<td>$885.00</td>
</tr>
<tr>
<td>Louise Chen</td>
<td>Cantor Fitzgerald</td>
<td>Maintains</td>
<td>Overweight</td>
<td>$885.00</td>
<td>$885.00</td>
</tr>
<tr>
<td>Louise Chen</td>
<td>Cantor Fitzgerald</td>
<td>Maintains</td>
<td>Overweight</td>
<td>$885.00</td>
<td>$885.00</td>
</tr>
<tr>
<td>Kerry Holford</td>
<td>Berenberg</td>
<td>Raises</td>
<td>Buy</td>
<td>$1000.00</td>
<td>$850.00</td>
</tr>
<tr>
<td>Chris Schott</td>
<td>JP Morgan</td>
<td>Raises</td>
<td>Overweight</td>
<td>$1000.00</td>
<td>$900.00</td>
</tr>
<tr>
<td>Carter Gould</td>
<td>Barclays</td>
<td>Raises</td>
<td>Overweight</td>
<td>$1025.00</td>
<td>$913.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to Eli Lilly. This insight gives a snapshot of analysts' perspectives on the current state of the company.</li>
<li>Rating: Analysts assign qualitative assessments to stocks, ranging from 'Outperform' to 'Underperform'. These ratings convey the analysts' expectations for the relative performance of Eli Lilly compared to the broader market.</li>
<li>Price Targets: Understanding forecasts, analysts offer estimates for Eli Lilly's future value. Examining the current and prior targets provides insight into analysts' changing expectations.</li>
</ul>
Analyzing these analyst evaluations alongside relevant financial metrics can provide a comprehensive view of Eli Lilly's market position. Stay informed and make data-driven decisions with the assistance of our Ratings Table.
<a href="https://www.benzinga.com/quote/LLY/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Eli Lilly analyst ratings.</a>
<h2>Discovering Eli Lilly: A Closer Look</h2>
Eli Lilly is a drug firm with a focus on neuroscience, cardiometabolic, cancer, and immunology. Lilly's key products include Verzenio for cancer; Mounjaro, Zepbound, Jardiance, Trulicity, Humalog, and Humulin for cardiometabolic; and Taltz and Olumiant for immunology.
<h3>Eli Lilly's Economic Impact: An Analysis</h3>
Market Capitalization Analysis: The company's market capitalization surpasses industry averages, showcasing a dominant size relative to peers and suggesting a strong market position.
Revenue Growth: Eli Lilly's remarkable performance in 3 months is evident. As of 30 June, 2024, the company achieved an impressive revenue growth rate of 35.98%. This signifies a substantial increase in the company's top-line earnings. In comparison to its industry peers, the company stands out with a growth rate higher than the average among peers in the Health Care sector.
Net Margin: Eli Lilly's net margin excels beyond industry benchmarks, reaching 26.25%. This signifies efficient cost management and strong financial health.
Return on Equity (ROE): Eli Lilly's financial strength is reflected in its exceptional ROE, which exceeds industry averages. With a remarkable ROE of 22.5%, the company showcases efficient use of equity capital and strong financial health.
Return on Assets (ROA): Eli Lilly's ROA surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 4.37% ROA, the company effectively utilizes its assets for optimal returns.
Debt Management: Eli Lilly's debt-to-equity ratio is below the industry average. With a ratio of 2.13, the company relies less on debt financing, maintaining a healthier balance between debt and equity, which can be viewed positively by investors.
<h2>The Core of Analyst Ratings: What Every Investor Should Know</h2>
Analyst ratings serve as essential indicators of stock performance, provided by experts in banking and financial systems. These specialists diligently analyze company financial statements, participate in conference calls, and engage with insiders to generate quarterly ratings for individual stocks.
Some analysts will also offer forecasts for metrics like growth estimates, earnings, and revenue to provide further guidance on stocks. Investors who use analyst ratings should note that this specialized advice comes from humans and may be subject to error.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;utm_source=benzinga-insights">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Cracking The Code: Understanding Analyst Reviews For Eli Lilly

Deutsche Bank analyst James Shin reiterates Eli Lilly (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>) with a Buy and maintains $1025 price target.

Reiteration

Deutsche Bank Reiterates Buy on Eli Lilly, Maintains $1025 Price Target

The demand for GLP-1 agonists, including Novo Nordisk A/S&#8217;s (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVO#NYSE">NVO</a>) Ozempic and Wegovy (semaglutide), a class of drugs used to manage diabetes and obesity, continues to grow.
Though initially developed for type 2 diabetes, GLP-1s have gained attention for their effectiveness in weight management. The FDA approval expanded use for <a target="_blank" href="https://www.benzinga.com/general/biotech/24/03/37567088/novo-nordisks-game-changer-fda-approves-weight-loss-sensation-wegovy-for-heart-health-potential-i" rel="noreferrer noopener">cardiovascular indication for Wegovy</a> and potential future applications for chronic kidney disease and non-alcoholic steatohepatitis (NASH) further underscores the <a target="_blank" href="https://www.benzinga.com/general/biotech/24/09/41034046/popular-ozempic-may-have-new-use-as-semaglutide-drugs-linked-to-reduced-overdose-risk-in-diabetic" rel="noreferrer noopener">promise of these treatments</a>.
The Forbes report <a target="_blank" href="https://www.forbes.com/sites/joshuacohen/2024/10/02/weight-loss-from-glp-1-drugs-not-as-robust-in-real-world-settings/" rel="noreferrer noopener">adds</a> that real-world evidence shows that weight loss from GLP-1 usage may not align with the outcomes seen in clinical trials.
A study published in the Journal of the American Medical Association (JAMA) revealed that patients, on average, achieved only a 3.7% weight reduction after one year on the drugs—lower than the results reported in controlled trials.
Also Read: <a target="_blank" href="https://www.benzinga.com/general/biotech/24/09/40986953/novo-nordisk-ceo-to-face-senate-scrutiny-over-high-ozempic-and-wegovy-prices-hearing-scheduled-on" rel="noreferrer noopener">Novo Nordisk CEO To Face Senate Scrutiny Over High Ozempic And Wegovy Prices, Hearing Scheduled On Tuesday</a>.
While patients have high expectations for substantial weight loss, the findings suggest that most individuals did not experience the same degree of benefit as seen in clinical settings.
However, those who persisted with GLP-1 therapy saw results comparable to those in clinical trials.
In another study published in 2023, researchers observed a modest average weight loss of 2.2% over 72 weeks among type 2 diabetes patients on GLP-1s.
Additionally, a pre-print analysis this year found that the real-world effectiveness of GLP-1s was less pronounced than in randomized controlled trials.
This difference underscores the challenge of replicating clinical trial success in everyday medical settings, where factors like medication adherence and real-life conditions are involved.
Persistence with GLP-1 medications is a significant issue. Forbes reported that only 15% of patients who started GLP-1 drugs for weight loss remained on them after two years, citing Prime Therapeutics, a pharmacy benefit manager.
Discontinuation rates were high, with just 29% continuing treatment after one year and a mere 15% after two years.
Other studies, including findings from Blue Cross Blue Shield, show that many patients stop GLP-1 therapy early, often within the first month, before achieving meaningful weight loss.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/general/biotech/24/10/41166018/medicare-drug-price-negotiation-program-gets-final-guidance-for-second-cycle-1-5b-savings-expecte" target="_blank" rel="noreferrer noopener">Medicare Drug Price Negotiation Program Gets Final Guidance For Second Cycle, $1.5B Savings Expected</a>.</li>
</ul>
Photo via Shutterstock

Media

Popular Weight Loss Drugs Like Ozempic Show Gap Between Clinical Trial Promises And Real-World Use, Study Reveals

<a href="https://www.texasattorneygeneral.gov/news/releases/attorney-general-ken-paxton-sues-big-pharma-drug-manufacturers-and-pharmacy-benefit-managers">https://www.texasattorneygeneral.gov/news/releases/attorney-general-ken-paxton-sues-big-pharma-drug-manufacturers-and-pharmacy-benefit-managers</a>
Texas Attorney General Ken Paxton sued major insulin manufacturers and pharmacy benefit managers (&quot;PBMs&quot;)&mdash;including Eli Lilly, Express Scripts, CVS Pharmacy, and others&mdash;over a conspiracy to increase prices of insulin.&nbsp;
Through this conspiracy, the manufacturers artificially and willingly raised the prices of insulin then paid a significant, undisclosed portion back to the PBMs as a quid pro quo for inclusion in the PBMs&#39; standard offerings. The PBMs then granted preferred status to the manufacturer whose drug has the highest list price while excluding lower priced drugs. These synthetic insulin drugs, which today cost the manufacturers less than $2 to produce and were originally priced at $20 when released in the late 1990s, now range between $300 and $700. In the last decade alone, the manufacturers who are defendants in the lawsuit have increased the prices of their insulins up to 1,000%. Attorney General Paxton is suing because the insulin pricing scheme violates the Texas Deceptive Trade Practices Act, constitutes unjust enrichment, and represents an unlawful civil conspiracy.
&quot;This is a disturbing conspiracy by which pharmaceutical companies were intentionally and artificially inflating the price of insulin. Big Pharma insulin manufacturers and PBMs worked together to take advantage of diabetes patients and drive prices as high as they could,&quot; said Attorney General Paxton. &quot;These companies acted illegally and unethically to enrich themselves, and we will hold them accountable.&quot;
According to the complaint, &quot;While the PBM Defendants represent that they perform their services on behalf of their clients (including Texas payors) and diabetics to lower drug prices, increase access to affordable drugs, and promote diabetic health, these representations are false. Rather, the PBM Defendants have worked in coordination with the Manufacturer Defendants to distort the market for diabetic treatments to their benefit at the expense of Texas diabetics and payors.&quot;
Liston &amp; Deas, David Nutt &amp; Associates, the Cicala Law Firm, and Foreman Watkins Krutz are serving as outside counsel.

Texas Attor­ney Gen­er­al Ken Pax­ton Sues Big Phar­ma Drug Man­u­fac­tur­ers And Phar­ma­cy Ben­e­fit Man­agers For Con­spir­a­cy

Hims &amp; Hers Health Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HIMS#NYSE">HIMS</a>) shares are trading lower Thursday in possible sympathy with Eli Lilly And Co&#8217;s (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>), after the U.S. Food and Drug Administration removed it from the weight-loss and diabetes drugs <a href="https://www.benzinga.com/markets/equities/24/09/40672154/eli-lilly-launches-discounted-mounjaro-and-zepbound-as-fight-against-compounded-imitations-escal">shortage list</a>.
What Happened: The FDA said in a <a href="https://www.fda.gov/drugs/drug-safety-and-availability/fda-clarifies-policies-compounders-national-glp-1-supply-begins-stabilize">statement</a> late Wednesday that Eli Lilly's supply of Mounjaro, which is used to treat diabetes, and weight-loss drug Zepbound can now keep up with current demand. 
Mounjaro had been on the regulator&#8217;s shortage list since late 2022, and Zepbound had been on the list since April.
&#8220;FDA confirmed with the drug's manufacturer that their stated product availability and manufacturing capacity can meet the present and projected national demand. Patients and prescribers may still see intermittent localized supply disruptions as the products move through the supply chain from the manufacturer and distributors to local pharmacies,&#8221; the FDA said.
Hims &amp; Hers Health shares are under pressure on Thursday as the firm sells cheaper versions of the aforementioned drugs, known as compounded drugs. Hims &amp; Hers said in May that it would&nbsp;begin selling compounded versions&nbsp;of GLP-1 injections. Shares surged on the news and have more than doubled since the start of the year.
Don&#8217;t Miss: <a href="https://www.benzinga.com/general/biotech/24/07/39656549/exclusive-glp-1-weight-loss-drugs-could-become-a-trillion-dollar-market-predicts-tema-etfs-ceo">EXCLUSIVE: GLP-1 Weight-Loss Drugs Could Become A Trillion-Dollar Market, Predicts Tema ETFs CEO</a>
The limited supply for weight-loss and diabetes drugs from Lilly and rival Novo Nordisk A/S (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVO#NYSE">NVO</a>) sparked a demand boom for compounded drugs, which are made by combining, mixing, or altering drug ingredients, per Reuters.
The report also indicates that regulators allow compounded versions of drugs to enter the market to meet demand when there is a shortage. When there is no shortage, compounded drug makers are reportedly unable to make &#8220;regular or inordinate amounts&#8221; of the drugs.
Lilly reportedly began selling vials of its lowest dose of Zepbound in the U.S. directly to consumers via its website to help push back against the rise of compounded versions of the drug. Novo Nordisk&#8217;s drugs were still listed on the FDA&#8217;s shortage list as of Thursday. 
HIMS Price Action: <a href="http://benzinga.com/quote/hims">Hims &amp; Hers Health shares</a> were down 8.92% at $17.26 at the time of publication, according to <a href="http://pro.benzinga.com">Benzinga Pro</a>.
Photo: Natalia Varlei from Shutterstock.

Movers

Hims & Hers Health Stock Is Tumbling Thursday: Here's Why

RBC Capital Markets initiated coverage on Tandem Diabetes Care, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TNDM#NASDAQ">TNDM</a>), a global insulin delivery and diabetes technology company that manufactures and sells advanced automated insulin delivery systems.
The analyst highlights several key growth drivers for Tandem, positioning it for sustained growth over the coming years driven by expansion into the U.S. Type 1 market with a 40% pump penetration (Tandem has a one-third share), which is expected to rise to the mid-60s and Type 2 market with 6% penetration.
The company is also seeking deeper penetration within existing accounts through product innovations.
The analyst also added that the rise of GLP-1s class drugs is not a major threat to insulin pump adoption.
GLP-1 drugs such as Novo Nordisk A/S&#8216; (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVO#NYSE">NVO</a>) semaglutide as Wegovy and Ozempic and Eli Lilly And Co&#8217;s (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>) tirzepatide as Zepbound and Mounjaro, have recently made waves.
RBC analyst highlights that insulin is essential for insulin-dependent patients, as GLP-1 medications cannot regenerate beta cells or halt their deterioration. As a result, the need for insulin remains.
The Type 2 diabetes population, which suffers from irreversible beta cell loss, is underserved.
The growing popularity of GLP-1 drugs may lead to earlier diagnoses of Type 2 diabetes and prompt insulin use, potentially expanding the market.
RBC initiated Tandem with an Outperform, with a price target of $65, citing a significant upside potential driven by earning revisions and multiple expansions.
RBC sees an opportunity for Tandem to achieve profitability over time and projects gross margins of 51% in 2024 or flat y/y to reflect the Mobi launch and investments in several ongoing R&amp;D initiatives.
The analyst sees a clear path for the company to reach its goal of approximately 65% margins, with Mobi accounting for about half of that progress. Further gains are anticipated from planned initiatives.
RBC projects breakeven for 2024, with positive adjusted EBITDA margins expected in the second half of the year.
Price Action: TNDM stock is down 0.37% at $40.92&nbsp;at the last check on Wednesday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/markets/equities/24/10/41146425/toyota-doubles-down-on-joby-aviation-500m-investment-powers-us-electric-air-taxi-certification-p" target="_blank" rel="noreferrer noopener">Toyota Doubles Down On Joby Aviation: $500M Investment Powers US Electric Air Taxi Certification, Production</a>.</li>
</ul>

Initiation

TNDM

Tandem Diabetes Insulin Pump Demand to Surge Despite Popular Demand Of Weight Loss Drugs, Bullish Analyst Says

Eli Lilly and Co (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>) is making a major move with a $4.5 billion investment to create the Lilly Medicine Foundry, a new research <a href="https://www.benzinga.com/quote/LLY/news">and manufacturing facility</a>.
The goal? To bolster its drug pipeline and develop faster, more efficient ways to bring treatments to market. This move builds on the massive success of its GLP-1 drugs, Mounjaro and Zepbound, which are revolutionizing the obesity treatment landscape and are projected to bring in nearly $19 billion in 2024.
<h2 class="wp-block-heading">From Molecules To Medicines, Says CEO Ricks</h2>
These drugs have quickly become some of the most talked-about products in the weight-loss market, alongside competitors like Novo Nordisk AS's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVO#NYSE">NVO</a>) Ozempic and Wegovy.
Beyond obesity drugs, Eli Lilly's pipeline includes 11 obesity-related treatments and ambitious plans to develop therapies for Alzheimer's, ALS, and other neurological conditions. CEO David Ricks emphasized the facility's role in scaling innovative molecules into life-saving medicines: "The idea is to take molecules from a bench in a lab to scaled for medicines in a pharmacy, and this research and development site will do that work."
Read Also: <a href="https://www.benzinga.com/general/biotech/24/10/41141028/eli-lilly-invests-4-5b-in-new-medicine-foundry-for-advanced-drug-manufacturing-to-push-us-pharma-">Eli Lilly Invests $4.5B In New Medicine Foundry for Advanced Drug Manufacturing To Push US Pharma Boundaries</a>
<h2 class="wp-block-heading">Eli Lilly Stock Chart Suggests Near-Term Headwinds</h2>
From a stock perspective, Eli Lilly has had a fantastic year, posting gains of 49% year-to-date and over 64% in the last 12 months. 
However, the technical signals suggest some headwinds in the near term.
<figure class="wp-block-image size-full"><a href="https://www.benzinga.com/pro/?utm_source=BZprocontent100224&amp;t=be2bearmibe3na1"><img loading="lazy" decoding="async" width="630" height="459" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/02091753/Screenshot-2024-10-02-at-6.45.52-PM.png" alt="" class="wp-image-576525" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/02091753/Screenshot-2024-10-02-at-6.45.52-PM.png 630w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/02091753/Screenshot-2024-10-02-at-6.45.52-PM-300x219.png 300w" sizes="(max-width: 630px) 100vw, 630px" /></a></figure>
<a href="https://www.benzinga.com/pro/?utm_source=BZprocontent100224&amp;t=be2bearmibe3na1">Chart created using Benzinga Pro</a>
Eli Lilly stock is trading below key short-term moving averages, including the eight-, 20-, and 50-day simple moving averages (SMA), which traditionally signal a short-to-medium-term bearish outlook. However, the stock trades well above the 200-day SMA, suggesting the long-term remains bullish.
<figure class="wp-block-image size-full"><a href="https://www.benzinga.com/pro/?utm_source=BZprocontent100224&amp;t=be2bearmibe3na1"><img loading="lazy" decoding="async" width="630" height="459" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/02091802/Screenshot-2024-10-02-at-6.47.13-PM.png" alt="" class="wp-image-576526" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/02091802/Screenshot-2024-10-02-at-6.47.13-PM.png 630w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/02091802/Screenshot-2024-10-02-at-6.47.13-PM-300x219.png 300w" sizes="(max-width: 630px) 100vw, 630px" /></a></figure>
<a href="https://www.benzinga.com/pro/?utm_source=BZprocontent100224&amp;t=be2bearmibe3na1">Chart created using Benzinga Pro</a>
The MACD (Moving Average Convergence/Divergence) indicator is negative at 6.28, reinforcing short-term selling pressure. The RSI (Relative Strength Index) lies in neutral territory at 40.89.
Yet, long-term investors might still see potential in the stock. With a 200-day moving average of $794.34, Eli Lilly could remain a solid investment for the future, particularly as its obesity drugs gain further market share.
While some volatility may persist in the short term, the long-term potential remains strong as Lilly continues to invest in its drug development pipeline.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/general/biotech/24/10/41137681/eli-lilly-nears-first-trillion-pharma-title-but-investors-caution-amid-sky-high-valuation">Eli Lilly Nears First Trillion Dollar Pharma Title, But Investors Caution Amid Sky-High Valuation</a></li>
</ul>
Photo: Shutterstock

Technicals

Eli Lilly Commits $4.5B To New Facility, Banking On Mounjaro, Zepbound's Weight Loss Success Despite Short-Term Stock Challenges

On Wednesday, Eli Lilly And Co. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>) announced a&nbsp;$4.5 billion&nbsp;investment to create the Lilly Medicine Foundry, a new center for advanced manufacturing <a target="_blank" href="https://www.benzinga.com/pressreleases/24/10/n41138388/lilly-announces-new-4-5-billion-site-the-lilly-medicine-foundry-to-drive-innovation-in-drug-produc" rel="noreferrer noopener">and drug development</a>.
As the company inches closer to becoming the first pharma company in the $1 trillion club, it aims to strengthen its standing as one of the top 10 most valuable firms in the U.S. by <a target="_blank" href="https://www.benzinga.com/general/biotech/24/10/41137681/eli-lilly-nears-first-trillion-pharma-title-but-investors-caution-amid-sky-high-valuation" rel="noreferrer noopener">outpacing its competitors</a>.
In a report, Eli Lilly said it plans to reinvest its revenues into R&amp;D, aiming to escape the pharmaceutical industry&#8217;s traditional boom-and-bust cycle.
The company says the new facility will allow Lilly to research new ways of producing medicines while scaling up the manufacturing of medicines for clinical trials.
Also Read: <a target="_blank" href="https://www.benzinga.com/general/biotech/24/09/41002452/eli-lillys-early-alzheimers-treatment-donanemab-scores-japanese-approval-its-second-largest-marke" rel="noreferrer noopener">Eli Lilly&#8217;s Early Alzheimer&#8217;s Treatment Donanemab Scores Japanese Approval, Its Second Largest Market</a>.
The Medicine Foundry will be the first-ever facility of its kind to combine research and manufacturing in a single location. It will be located in&nbsp;Indiana&#8217;s&nbsp;LEAP Research and Innovation District in&nbsp;Lebanon, Indiana, and will expand the company&#8217;s investment there to more than&nbsp;$13 billion.&nbsp;
This new facility will add to Lilly&#8217;s previous manufacturing commitments in&nbsp;Lebanon, which include a $2.1 billion investment announced in May 2022 to expand its network for active ingredients and new modalities, such as genetic medicines.
In&nbsp;April 2023, the company announced an&nbsp;<a target="_blank" href="https://c212.net/c/link/?t=0&amp;l=en&amp;o=4268657-1&amp;h=1606463900&amp;u=https%3A%2F%2Flilly.mediaroom.com%2F2023-04-17-Lilly-to-Make-Record-Breaking-Investment-in-Indiana-Manufacturing-Facilities&amp;a=additional+%241.6+billion" rel="noreferrer noopener">additional&nbsp;$1.6 billion</a> investment.
In&nbsp;May 2024, Lilly announced an&nbsp;<a target="_blank" href="https://c212.net/c/link/?t=0&amp;l=en&amp;o=4268657-1&amp;h=647148840&amp;u=https%3A%2F%2Flilly.mediaroom.com%2F2024-05-24-Lilly-Increases-Manufacturing-Investment-to-9-Billion-at-Newest-Indiana-Site-to-Boost-API-Production-for-Tirzepatide-and-Pipeline-Medicines&amp;a=additional+%245.3+billion" rel="noreferrer noopener">additional&nbsp;$5.3 billion</a> commitment to enhance its capacity to manufacture active pharmaceutical ingredients for its latest diabetes and obesity medicines, marking the largest single investment in active pharmaceutical ingredients production in U.S. history.
Opening in late 2027, the facility will increase Lilly&#8217;s total capital commitment in&nbsp;the United States&nbsp;to more than&nbsp;$23 billion&nbsp;since 2020. It is trying to stay ahead of its close competitor, Novo Nordisk A/S&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVO#NYSE">NVO</a>).
Once fully operational, the Medicine Foundry is expected to add 400 full-time jobs.
Price Action: At last check on Wednesday, LLY stock was down 0.39% at $881.00 during the premarket session.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/general/biotech/24/10/41137681/eli-lilly-nears-first-trillion-pharma-title-but-investors-caution-amid-sky-high-valuation" target="_blank" rel="noreferrer noopener">Eli Lilly Nears First Trillion Dollar Pharma Title, But Investors Caution Amid Sky-High Valuation</a></li>
</ul>
Photo via Shutterstock

Eli Lilly Invests $4.5B In New Medicine Foundry for Advanced Drug Manufacturing To Push US Pharma Boundaries

This facility will give Lilly the ability to research new ways of producing medicines, while also scaling up manufacturing of medicines for clinical trials.
Opening in late 2027, the facility will increase Lilly&#39;s total capital commitment in&nbsp;the United States&nbsp;to more than&nbsp;$23 billion&nbsp;since 2020

Eli Lilly Reveals $4.5B Investment To Create The Lilly Medicine Foundry For Advanced Manufacturing And Drug Development

U.S. Pharmaceutical giant Eli Lilly And Co (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>) is riding high on the popularity of weight loss drugs and is on the brink of becoming the world's first trillion-dollar pharmaceutical company.
According to data from <a target="_blank" href="https://www.benzinga.com/pro/feature/newsfeed" rel="noreferrer noopener">Benzinga Pro</a>, the company's market cap stood at $796.4 billion, and its enterprise value at $821.9 billion.
The stock had almost doubled since May 2022 and outpaced S&amp;P500 and NASDAQ when the company received FDA approval for Mounjaro (tirzepatide) as an adjunct to diet and exercise <a target="_blank" href="https://www.benzinga.com/general/biotech/22/05/27213975/fda-approves-eli-lillys-new-type-2-diabetes-treatment-tirzepatide" rel="noreferrer noopener">for type 2 diabetes</a>.
<figure class="wp-block-image size-full"><img loading="lazy" decoding="async" width="750" height="650" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/02064204/newplot-1-1.png" alt="" class="wp-image-576166" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/02064204/newplot-1-1.png 750w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/02064204/newplot-1-1-300x260.png 300w" sizes="(max-width: 750px) 100vw, 750px" /></figure>
In November, the FDA approved tirzepatide, dubbed Zepbound, <a target="_blank" href="https://www.benzinga.com/general/biotech/23/11/35680340/weight-loss-drug-competition-fda-approves-expanded-use-of-eli-lillys-blockbuster-tirzepatide-for-" rel="noreferrer noopener">for weight loss</a>.
In a Financial Times <a target="_blank" href="https://www.ft.com/content/ed81ca79-1fd6-48ea-8e50-246d0849c3f5" rel="noreferrer noopener">report</a>, CEO Dave Ricks recalls a time when Eli Lilly was struggling. In the late 2000s, the loss of patents on its psychiatric drugs, including Prozac and Cymbalta, pushed the company near all-time lows.
Also Read: <a target="_blank" href="https://www.benzinga.com/general/biotech/24/10/41118751/eli-lilly-eyes-new-trials-for-weight-loss-drugs-in-non-obese-patients" rel="noreferrer noopener">Eli Lilly Eyes New Trials For Weight-Loss Drugs In Non-Obese Patients</a>.
<figure class="wp-block-image size-full"><img loading="lazy" decoding="async" width="750" height="650" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/02064215/newplot-2.png" alt="" class="wp-image-576167" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/02064215/newplot-2.png 750w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/02064215/newplot-2-300x260.png 300w" sizes="(max-width: 750px) 100vw, 750px" /></figure>
However, the company's fortunes have since reversed, with Eli Lilly now investing $20 billion in production facilities to meet the growing demand for its blockbuster drugs, and it is trying to stay ahead of its close competitor Novo Nordisk A/S (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVO#NYSE">NVO</a>).
The company is also developing orforglipron, which could be the first small-molecule weight-loss pill when it launches in 2026, giving Eli Lilly a two-year lead before rivals catch up.
However, investors are cautious, noting that Eli Lilly's valuation is lofty, currently at $842 billion, 54x projected earnings over the next 12 months.
A top-10 shareholder of Eli Lilly told the Financial Times that investors are rushing into Eli Lilly, pushing it higher, but it's already priced for perfection. The shareholder warned that investors could face significant risks if concerns arise about competition from the ten other companies with weight-loss drugs or potential pricing pressures.
The company aims to strengthen its standing as one of the top 10 most valuable firms in the U.S. by outpacing its competitors.
Eli Lilly plans to reinvest its revenues into R&amp;D, aiming to escape the pharmaceutical industry's traditional boom-and-bust cycle.
CEO Ricks says the company is preparing for the future, particularly as it nears a "patent cliff" for its weight-loss drugs in the mid-2030s. By then, competition and pricing pressure could significantly affect profits.
The company is working on new treatments for obesity-related conditions, such as sleep apnea and cardiovascular disease, which could secure broader insurance coverage for its drugs.
Price Action: LLY stock closed at $884.55&nbsp;on Tuesday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/government/24/10/41127863/despite-nvidia-selloff-bidens-law-and-taiwan-semis-advantage-offer-growth-potential" target="_blank" rel="noreferrer noopener">Despite Nvidia Selloff, Biden's Law and Taiwan Semi's Advantage Offer Growth Potential</a>.</li>
</ul>
Photo via Eli Lilly and Company

Eli Lilly Nears First Trillion Dollar Pharma Title, But Investors Caution Amid Sky-High Valuation

Monday, the U.S. Department of Health and Human Services (HHS) announced that Medicare enrollees will benefit from reduced prices on 54 drugs through Medicare Part B, effective from October 1, 2024, to December 31, 2024.
The <a target="_blank" href="https://www.hhs.gov/about/news/2024/09/30/hhs-announces-cost-savings-for-prescription-drugs-thanks-to-medicare-inflation-rebate-program.html" rel="noreferrer noopener">program</a> aims to counter drug price hikes that exceed inflation, providing financial relief for over 822,000 Medicare beneficiaries who rely on these medications to treat conditions like cancer, osteoporosis, and pneumonia.
Also Read: <a target="_blank" href="https://www.benzinga.com/general/biotech/24/08/40422798/doctors-struggle-to-secure-medicare-coverage-for-heart-patients-on-novo-nordisks-wegovy" rel="noreferrer noopener">Doctors Struggle to Secure Medicare Coverage for Heart Patients on Novo Nordisk&#8217;s Wegovy</a>
HHS Secretary Xavier Becerra emphasized that the Biden administration&#8217;s prescription drug policies are making a tangible impact on seniors and people with disabilities by reducing out-of-pocket costs.
According to Chiquita Brooks-LaSure, CMS Administrator, some Medicare beneficiaries could see daily savings ranging from $1 to as much as $3,854 on drugs included in the rebate program.
For example, a cancer patient using Novartis&#8217; AGs (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVS#NYSE">NVS</a>) Kymriah could save up to $3,000.
Brooks-LaSure also noted that the law disincentivizes drug companies from raising prices faster than inflation, which helps protect Medicare beneficiaries from sharp price increases.
The Inflation Reduction Act&#8217;s initiatives extend beyond 2024. In August, the administration reached new agreements to reduce prices for ten additional high-cost drugs.
Once these prices take effect in 2026, Medicare is projected to save an estimated $6 billion, while beneficiaries could see a reduction of $1.5 billion in <a target="_blank" href="https://www.benzinga.com/general/biotech/24/08/40397706/biden-administration-targets-6b-savings-through-medicare-drug-price-negotiations" rel="noreferrer noopener">out-of-pocket expenses</a>.
Starting in 2025, Medicare Part D enrollees will further benefit from a $2,000 annual cap on prescription drug costs, down from the current cap of $3,500 for those with high expenses.
According to some analysts,&nbsp;Novo Nordisk A/S&#8217; (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVO#NYSE">NVO</a>)&nbsp;blockbuster diabetes drug&nbsp;Ozempic might be included, along with several other well-known medications, in the next round of negotiations, which <a target="_blank" href="https://www.benzinga.com/general/biotech/24/08/40534249/novo-nordisks-ozempic-might-be-among-2027-medicare-price-negotiation-targets" rel="noreferrer noopener">is set for 2027</a>.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/markets/equities/24/10/41124151/tpg-gic-agree-to-buy-techem-for-7-5b-look-to-expand-across-europe-and-beyond" target="_blank" rel="noreferrer noopener">TPG, GIC Agree To Buy Techem For $7.5B: Look To Expand &#8216;Across Europe And Beyond&#8217;</a></li>
</ul>
Photo via Shutterstock

Regulations

US HHS Reveal Cost Savings For 54 Prescription Drugs Including Novartis' Cancer Drug, Ozempic Could be Next

Investors with a lot of money to spend have taken a bearish stance on Eli Lilly (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>).
And retail traders should know.
We noticed this today when the trades showed up on publicly available options history that we track here at Benzinga.
Whether these are institutions or just wealthy individuals, we don't know. But when something this big happens with LLY, it often means somebody knows something is about to happen.
So how do we know what these investors just did? 
Today, <a href="https://pro.benzinga.com/?utm_source=insights">Benzinga</a>'s options scanner spotted 28 uncommon options trades for Eli Lilly.
This isn't normal.
The overall sentiment of these big-money traders is split between 28% bullish and 46%, bearish.
Out of all of the special options we uncovered, 5 are puts, for a total amount of $190,255, and 23 are calls, for a total amount of $1,136,270.
<h3>What's The Price Target?</h3>
Based on the trading activity, it appears that the significant investors are aiming for a price territory stretching from $800.0 to $1060.0 for Eli Lilly over the recent three months. 
<h3>Volume &amp; Open Interest Trends</h3>
Looking at the volume and open interest is an insightful way to conduct due diligence on a stock.
This data can help you track the liquidity and interest for Eli Lilly's options for a given strike price.
Below, we can observe the evolution of the volume and open interest of calls and puts, respectively, for all of Eli Lilly's whale activity within a strike price range from $800.0 to $1060.0 in the last 30 days. 
<h3>Eli Lilly Option Activity Analysis: Last 30 Days</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1727794897_0.png" alt="Options Call Chart" />
<h3>Biggest Options Spotted:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th style="text-align: right;">Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>LLY</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>12/20/24</td>
<td>$70.35</td>
<td>$68.8</td>
<td>$68.8</td>
<td>$880.00</td>
<td>$275.2K</td>
<td>242</td>
<td style="text-align: right;">5</td>
</tr>
<tr>
<td>LLY</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>01/17/25</td>
<td>$67.6</td>
<td>$65.4</td>
<td>$67.6</td>
<td>$900.00</td>
<td>$67.6K</td>
<td>1.9K</td>
<td style="text-align: right;">1</td>
</tr>
<tr>
<td>LLY</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>01/17/25</td>
<td>$68.15</td>
<td>$66.5</td>
<td>$66.5</td>
<td>$900.00</td>
<td>$66.5K</td>
<td>1.9K</td>
<td style="text-align: right;">12</td>
</tr>
<tr>
<td>LLY</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>10/04/24</td>
<td>$4.25</td>
<td>$3.1</td>
<td>$3.1</td>
<td>$860.00</td>
<td>$62.0K</td>
<td>975</td>
<td style="text-align: right;">334</td>
</tr>
<tr>
<td>LLY</td>
<td>CALL</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>11/01/24</td>
<td>$46.7</td>
<td>$45.25</td>
<td>$45.92</td>
<td>$880.00</td>
<td>$55.1K</td>
<td>25</td>
<td style="text-align: right;">13</td>
</tr>
</tbody>
</table>

<h3>About Eli Lilly</h3>
Eli Lilly is a drug firm with a focus on neuroscience, cardiometabolic, cancer, and immunology. Lilly's key products include Verzenio for cancer; Mounjaro, Zepbound, Jardiance, Trulicity, Humalog, and Humulin for cardiometabolic; and Taltz and Olumiant for immunology.
After a thorough review of the options trading surrounding Eli Lilly, we move to examine the company in more detail. This includes an assessment of its current market status and performance.
<h3>Where Is Eli Lilly Standing Right Now?</h3>
<ul>
<li>Currently trading with a volume of 609,446, the LLY's price is up by 0.24%, now at $888.05. </li>
<li>RSI readings suggest the stock is currently may be approaching oversold.</li>
<li>Anticipated earnings release is in 29 days.</li>
</ul>
<h3>What The Experts Say On Eli Lilly</h3>
Over the past month, 4 industry analysts have shared their insights on this stock, proposing an average target price of $982.5.
Turn $1000 into $1270 in just 20 days?
20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. <a href="https://www.benzinga.com/premium/ideas/options-moneyline-2/?t=Moop1arja3be22op14&amp;utm_source=benzinga-insights">Click here for access</a>. 
&#x2A; Reflecting concerns, an analyst from Cantor Fitzgerald lowers its rating to Overweight with a new price target of $885. 
&#x2A; An analyst from Citigroup has revised its rating downward to Buy, adjusting the price target to $1060. 
&#x2A; An analyst from JP Morgan has decided to maintain their Overweight rating on Eli Lilly, which currently sits at a price target of $1100. 
&#x2A; Reflecting concerns, an analyst from Cantor Fitzgerald lowers its rating to Overweight with a new price target of $885.
Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating themselves, adapting their strategies, monitoring multiple indicators, and keeping a close eye on market movements. Stay informed about the latest Eli Lilly options trades with real-time alerts from <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>.

Options

Eli Lilly's Options: A Look at What the Big Money is Thinking

Pharmaceutical giant Eli Lilly and Co (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>) is reportedly exploring broader applications for its popular weight-loss drugs, <a target="_blank" href="https://www.benzinga.com/analyst-ratings/analyst-color/24/04/38055169/citi-monitors-competitive-threats-to-eli-lilly-says-it-is-positioned-to-maintain-le" rel="noreferrer noopener">Mounjaro and Zepbound</a>.
The company is considering clinical trials targeting individuals with a lower body mass index (BMI), expanding beyond the obese patient population to include those not classified as overweight but at risk of gaining weight.
In a Financial Times <a target="_blank" href="https://www.ft.com/content/b2da2ca6-822e-4d42-bee4-e500522531e7" rel="noreferrer noopener">report</a>, CEO Dave Ricks highlighted the company&#8217;s plans to study the effects of these medications on people with a BMI of 25, compared to the standard BMI threshold of 27 in Europe and the U.S. for clinical trials.
Also Read: <a target="_blank" href="https://www.benzinga.com/general/biotech/24/09/40736321/battle-over-compounded-weight-loss-medications-sustainability-and-regulation" rel="noreferrer noopener">Battle Over Compounded Weight-Loss Medications &#8211; Sustainability and Regulation</a>.
Ricks hinted that the company&#8217;s long-term goal may involve using GLP-1 class drugs for overall health maintenance.
He told FT that these drugs might benefit people who are not yet overweight but are seeking to prevent conditions such as diabetes, vascular dementia, or strokes.
Eli Lilly has already been studying Zepbound in patients with a BMI of 27 or above, especially those facing weight-related health issues, but is now considering lowering that threshold to include more individuals, particularly for its <a target="_blank" href="https://www.benzinga.com/analyst-ratings/analyst-color/24/07/39753273/with-oral-anti-obesity-candidate-development-pfizer-seeks-relevant-and-competitive-" rel="noreferrer noopener">experimental weight-loss pill</a>, orforglipron.
Eli Lilly has also been vocal in discouraging the use of Zepbound for cosmetic purposes, particularly among wealthy individuals and celebrities using the drug off-label.
The company has argued that the limited supply of these medications should be reserved for diabetic and obese patients who need them most.
Ricks reiterated the company&#8217;s stance, saying they are &#8220;not comfortable&#8221; with the drug&#8217;s off-label use for vanity.
In a bold move, Eli Lilly aired a commercial during the Academy Awards to emphasize that Zepbound should not be used simply to fit into a smaller dress or tuxedo for a special event.
Price Action: LLY stock is up 0.32% at $888.73 at the last check on Tuesday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/news/earnings/24/10/41116026/mccormick-stock-gains-after-q3-earnings-beat-raised-eps-outlook" target="_blank" rel="noreferrer noopener">McCormick Stock Gains After Q3 Earnings Beat, Raised EPS Outlook</a>.</li>
</ul>
Image by Mohammed_Al_Ali via Shutterstock

Eli Lilly Eyes New Trials For Weight-Loss Drugs In Non-Obese Patients

In a groundbreaking move, Eli Lilly (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>) is set to test its weight-loss medications on individuals who are not overweight but are at risk of gaining weight.
What Happened: Dave Ricks, CEO of Eli Lilly, announced that the company is considering lowering the BMI threshold for its anti-obesity drugs, Mounjaro and Zepbound. Currently, the BMI cut-off for trials is 27 in the U.S. and northern Europe. Ricks suggested that a BMI of 25 might be more suitable, Financial Times <a href="https://www.ft.com/content/b2da2ca6-822e-4d42-bee4-e500522531e7?ref=biztoc.com">reported</a> on Monday.
Ricks pointed out that trials for Zepbound and the experimental weight-loss pill orforglipron included patients with a BMI of 30 and above, or those with a BMI of 27 and above with weight-related health issues. He argued for lowering the threshold, especially for orforglipron, which results in more modest weight loss.
Ricks also mentioned the potential for expanding the use of these drugs to individuals with a BMI below 25 who are classified as having a healthy weight but are at risk of conditions like diabetes or vascular dementia. He emphasized the need to consider different BMI cut-offs for certain ethnic groups, such as Pacific Islanders, who are known to contract type-two diabetes earlier and at a lower BMI.
See Also: <a href="https://www.benzinga.com/news/large-cap/24/09/41091446/cvs-health-in-focus-as-activist-investor-prepares-for-high-level-talks?itm_source=parsely-api" target="_blank" rel="noreferrer noopener">CVS Health in Focus as Activist Investor Prepares for High-Level Talks</a>
The demand for Zepbound and Novo Nordisk's Wegovy has led to shortages, prompting both companies to invest heavily in manufacturing capacity. Eli Lilly has discouraged the off-label use of Zepbound for cosmetic purposes, emphasizing the need to prioritize diabetic and obese patients.
Why It Matters: The decision to lower the BMI threshold for weight-loss drug trials comes at a time when Eli Lilly is experiencing significant success in the weight-loss drug market. The company&#8217;s stock <a href="https://www.benzinga.com/general/biotech/24/09/41036415/eli-lilly-stock-soars-in-2024-on-weight-loss-drug-success-now-the-company-wants-medical-records-o">has soared due </a>to the success of its weight-loss medications. However, the company is also facing competition from knockoff drugs, which it claims could be unsafe.
Additionally, Eli Lilly<a href="https://www.benzinga.com/general/health-care/24/09/40751984/stock-of-the-day-heres-why-weight-loss-drug-maker-eli-lilly-has-reversed"> stock hit resistance</a> after a significant rally. This indicates that while the company is performing well, it is also navigating market challenges and competition.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/markets/cannabis/24/09/41067503/has-medical-marijuana-been-forgotten-in-cannabis-reform-its-therapeutic-benefits-are-critical?itm_source=parsely-api" target="_blank" rel="noreferrer noopener">Has Medical Marijuana Been Forgotten In Cannabis Reform? &#8216;Its Therapeutic Benefits Are Critical&#8217;</a></li>
</ul>
Photo via Shutterstock
This story was generated using <a href="https://www.benzinga.com/author/benzinga-neuro">Benzinga Neuro</a> and edited by <a href="https://www.benzinga.com/topic/Pooja-Rajkumari" target="_blank" rel="noreferrer noopener">Pooja Rajkumari</a>

Eli Lilly Aims To Expand Weight-Loss Drug Trials To Those At Risk, Not Just Overweight

STOCK RISES THOUGHT THE DAY AND HITS HIGH AT 3:55 PM EDT
<figure class="wp-block-image size-full is-resized"><img loading="lazy" decoding="async" width="822" height="799" src="https://contributor-assets.benzinga.com/wp-content/uploads/2024/09/30203158/Screen-Shot-2024-09-30-at-4.28.14-PM.png" alt="" class="wp-image-1697" style="width:624px" srcset="https://contributor-assets.benzinga.com/wp-content/uploads/2024/09/30203158/Screen-Shot-2024-09-30-at-4.28.14-PM.png 822w,https://contributor-assets.benzinga.com/wp-content/uploads/2024/09/30203158/Screen-Shot-2024-09-30-at-4.28.14-PM-300x292.png 300w,https://contributor-assets.benzinga.com/wp-content/uploads/2024/09/30203158/Screen-Shot-2024-09-30-at-4.28.14-PM-768x747.png 768w" sizes="(max-width: 822px) 100vw, 822px" /></figure>
ELI LILLY Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>) today experienced a Power Inflow, a significant event for those who follow where smart money goes and value order flow analytics in their trading decisions.&nbsp;
Today, at 10:10 AM on September 30th, a significant trading signal occurred for Eli Lilly, Inc. as it demonstrated a Power Inflow at $872. This indicator is crucial for traders who want to know directionally where institutions and so-called "smart money" moves in the market. They see the value of utilizing order flow analytics to guide their trading decisions. The Power Inflow points to a possible uptrend in Eli Lilly&#8217;s stock, marking a potential entry point for traders looking to capitalize on the expected upward movement. Traders with this signal closely watch for sustained momentum in Eli Lilly&#8217;s stock price, interpreting this event as a bullish sign.
Signal description
Order flow analytics, aka transaction or market flow analysis, separate and study both the retail and institutional volume rate of orders (flow). It involves analyzing the flow of buy and sell orders, along with size, timing, and other associated characteristics and patterns, to gain insights and make more informed trading decisions. This particular indicator is interpreted as a bullish signal by active traders.&nbsp;
The Power Inflow occurs within the first two hours of the market open and generally signals the trend that helps gauge the stock&#8217;s overall direction, powered by institutional activity in the stock, for the remainder of the day.&nbsp;
By incorporating order flow analytics into their trading strategies, market participants can better interpret market conditions, identify trading opportunities, and potentially improve their trading performance. But let's not forget that while watching smart money flow can provide valuable insights, it is crucial to incorporate effective risk management strategies to protect capital and mitigate potential losses. Employing a consistent and effective risk management plan helps traders navigate the uncertainties of the market in a more controlled and calculated manner, increasing the likelihood of long-term success
If you want to stay updated on the latest options trades for LLY, <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> gives you real-time options trades alerts.&nbsp;
<a href="https://benzinga.com/apis?_gl=1&#x2A;1hlgn5i&#x2A;_ga&#x2A;MTY1NjE2NTYxMi4xNzE0NzQ4MTAy&#x2A;_ga_V7ZK73W7N0&#x2A;MTcxNDc0ODEwMi4xLjEuMTcxNDc0ODQyOC4wLjAuMA..">Market News and Data brought to you by Benzinga APIs</a> and include firms, like <a href="https://finitusa.com/en/">Finit USA</a>, responsible for parts of the data within this article. 
&#xA9; 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
After Market Close UPDATE:
The price at the time of the Power Inflow was $872. The returns on the High price ($887.07) and Close price ($885.94) after the Power Inflow are respectively 1.6% and 1.5%. The result underlines the importance of a trading plan that includes Profit Targets and Stop Losses that reflect your appetite for risk. The results were close today but that is not always the case.
Past results are not indicative of future results

Signals

Tradepulse Power Inflow Alert: Eli Lilly And Company Climbs 15 Points

Sanofi&nbsp;(NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/sny#NASDAQ">SNY</a>) and partner Regeneron&nbsp;(NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/regn#NASDAQ">REGN</a>) announced that the FDA has approved their blockbuster drug, Dupixent, for its sixth indication &mdash; chronic obstructive pulmonary disease (COPD) &mdash; in the United States. The approved indication is as an add-on maintenance treatment of adults with inadequately controlled COPD and an eosinophilic phenotype. With this approval, Dupixent became the first biologic treatment approved for COPD in the United States.
Dupixent was approved for treating COPD with raised blood eosinophils in the EU in July 2024. Dupixent was also approved for the COPD indication in China last week.
Sanofi&#39;s stock has gained 16.0% so far this year compared with an increase of 20.2% for the large cap <a href="https://www.zacks.com/stocks/industry-rank/industry/large-cap-pharmaceuticals-225">pharmaceutical industry</a>.
<img alt="Zacks Investment Research" src="https://staticx-tuner.zacks.com/images/articles/charts/e4/79621.jpg?v=1565371588" style="height:310px; width:624px" />
Image Source: Zacks Investment Research
The approval for COPD, a respiratory disease that causes progressive lung function decline, was based on data from two studies. The NOTUS and BOREAS studies met their primary endpoint by showing that Dupixent significantly reduced moderate or severe acute COPD exacerbations by 30% and 34%, respectively. Dupixent also showed improvements in lung function and health-related quality of life compared to placebo.
Earlier this year, the FDA extended its decision on a supplemental biologics license application seeking approval of Dupixent for COPD from June 27 to Sept. 27.
<h3>Dupixent &ndash; Key Top-Line Driver For SNY, REGN</h3>
Dupixent is currently approved in several countries, including the United States and EU, for five other type II inflammatory diseases, namely severe chronic rhinosinusitis with nasal polyposis, severe asthma, moderate-to-severe atopic dermatitis, eosinophilic esophagitis and prurigo nodularis.
Dupixent is being jointly marketed by Regeneron and&nbsp;Sanofi&nbsp;under a global collaboration agreement. Sanofi records global net product sales of Dupixent, while Regeneron records its share of profits/losses in connection with the global sales of the drug. The approval for the COPD indication can significantly boost sales of Dupixent. Some analysts expect total sales of Dupixent for COPD to be around $6 billion.
Dupixent is a key top-line driver for both Sanofi and Regeneron on strong demand trends. In the first half of 2024, Dupixent generated global product sales of $&euro;6.1 billion, which were recorded by Sanofi, representing growth of 27.1% at a constant exchange rate. Sanofi expects Dupixent to achieve more than &euro;13 billion in sales in 2024.
For Regeneron, Dupixent generated collaboration revenues of $2.06 billion in the first half, up 18% year over year.
<h2>SNY Zacks Rank and Other Stocks to Consider</h2>
Sanofi currently has a Zacks Rank #2 (Buy).
<div class="chart_embed">
<h3>Sanofi Stock Price and Consensus</h3>
<a href="https://www.zacks.com/stock/chart/SNY/price-consensus-chart?icid=chart-SNY-price-consensus-chart"><img alt="Sanofi Price and Consensus" src="https://staticx-tuner.zacks.com/images/charts/44/1727692069.png" style="height:287px; width:624px" title="" /> </a>
<a href="https://www.zacks.com/stock/chart/SNY/price-consensus-chart?icid=chart-SNY-price-consensus-chart">Sanofi price-consensus-chart</a> | <a href="https://www.zacks.com/stock/quote/SNY?icid=chart-SNY-price-consensus-chart">Sanofi Quote</a>
</div>
Some other top-ranked drug/biotech companies are Eli Lilly (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/lly#NYSE">LLY</a>) and Pfizer (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/pfe#NYSE">PFE</a>). While Lilly sports a Zacks Rank #1 (Strong Buy), Pfizer has a Zacks Rank #2. You can see <a href="https://www.zacks.com/stocks/buy-list/?ADID=zp_1link&amp;ICID=zpi%20_1link">the complete list of today&#39;s Zacks #1 Rank stocks here</a>.
Estimates for Lilly&#39;s 2024 earnings have risen from $13.79 to $16.49 per share over the past 60 days. For 2025, earnings estimates have risen from $19.44 to $23.97 per share over the same timeframe. Year to date, Lilly&#39;s stock has risen 50.5%.
Lilly beat estimates in each of the last four quarters, delivering a four-quarter average earnings surprise of 69.07%.
The Zacks Consensus Estimate for Pfizer&#39;s earnings has risen from $2.38 to $2.62 per share for 2024 over the past 60 days, while that for 2025 has risen from $2.74 per share to $2.85 per share. Pfizer&#39;s shares have risen 1.0% year to date.
Pfizer beat estimates in each of the last four quarters, delivering a four-quarter average earnings surprise of 69.82%.
<a href="https://www.zacks.com/">Zacks Investment Research</a>

REGN

Sanofi, Regeneron's Dupixent Gets FDA Approval For COPD

Eli Lilly GLP-1 shortage officially ends, hurting Hims & Hers

Eli Lilly weight loss therapy on track for NHS rollout in England

Fall 2024 Snapshot Of The S&P 500's Market Cap

Pharma Stocks Losing Ground After A Remarkable Rally, Downgrading PPH

Is Hims & Hers rally at risk as GLP-1 shortages ease?

NIE: Updates On Finances And Distributions Following Release Of Semi-Annual Report

Wall Street Lunch: 'Insane' Nvidia Demand

If I Had To Invest $150,000 Right Now, Here's What I Would Buy

Trending stocks this week as strong jobs report underscore resilience of U.S. economy

Can Novo, Lilly take credit for U.S. obesity rate decline?

AAPL

ACTV

AFMC

AFSM

AMZN

ARKK

AVGO

AVUV

BAPR

BLBD

CMCSA

CRWD

CSCO

CTLT

CTSH

DELL

EBAY

EXPE

FOXA

GILD

GOOG

GOOGL

ICVT

IVOO

IVOV

LEVI

LULU

MAGS

MSFT

NONOF

NVDA

PLTR

QQQM

SAVE

SCHD

SCHG

SPLG

SPLV

SPMD

SPMO

SPMV

SPSM

SPUS

SPUU

SPVM

SPVU

SPXE

SPXL

SPXN

SPXS

SPXT

SPXU

SPXV

SPYD

SPYG

SPYV

SPYX

SQEW

SQLV

SSNC

SSNLF

SSPY

SVAL

SYLD

TMDV

TPHD

TPLC

TPSC

UAUG

UJAN

UMAR

UMAY

UOCT

UPRO

USMC

USMF

USVM

VRSN

Screenshot 2024-09-30 at 9.13.36 PM

TNXP

VRTX

The Rush For Non-Addictive Painkillers To Counter The Opioid Crisis Puts Two Companies Closer To FDA Decisions

Screenshot 2024-09-10 at 4.29.40 PM

BRTX

Armed With Its Patent Portfolio, BioRestorative Therapies Has Success In The Laboratory And At The Negotiating Table: Is Profitability Close Behind?

Screenshot 2024-08-22 at 5.32.58 PM

RDHL

RedHill&#39;s Opaganib Shows Diabetes And Obesity Potential With Positive In Vivo Results

Screenshot 2024-07-10 at 9.08.28 PM

AXSM

A Redux Of The Lyrica-Cymbalta Fibromyalgia War Of The 2010s May Look More Like David Vs. Goliath

Screenshot 2024-06-18 at 1.15.14 AM

BioRestorative Therapies Enters Preclinical Assessment Of Its Patented Stem-Cell Technology Prior To First-In-Human Studies

Screenshot 2024-05-16 at 5.52.00 PM

ELAB

Elevai Labs (NASDAQ: ELAB) Acquires Rights To Develop Muscle Loss Prevention Assets For Anticipated Use In Anti-Obesity Treatments, Launches Two New Subsidiaries

Screenshot 2024-02-24 at 12.03.42 AM

ABBV

New Drug Study Shows Improving Sleep Quality Can Relieve Fibromyalgia Pain

Comments

Eli Lilly

ニュース

最新ニュース Eli Lilly (NYSE:LLY) 株価情報

月曜日, 8 12, 2024

金曜日, 7 26, 2024

水曜日, 6 19, 2024

火曜日, 5 07, 2024

こんな人も見ています

ニュース

パートナーシップ

ベンジンガ・グローバル